Idelalisib/rituximab/bendamustine, N = 207 | Placebo/rituximab/bendamustine, N = 209 | |||||
---|---|---|---|---|---|---|
Dimensions | Baseline | Week 24 | Week 48 | Baseline | Week 24 | Week 48 |
Anxiety/Depression | ||||||
Level 1 | 113 (57.1) | 102 (65.8) | 85 (66.4) | 117 (59.1) | 91 (60.3) | 70 (66.7) |
Level 2 | 84 (42.4) | 50 (32.3) | 41 (32.0) | 75 (37.9) | 55 (36.4) | 32 (30.5) |
Level 3 | 1 (0.5) | 3 (1.9) | 2 (1.6) | 6 (3.0) | 5 (3.3) | 3 (2.9) |
Mobility | ||||||
Level 1 | 145 (73.6) | 119 (76.8) | 94 (73.4) | 142 (71.4) | 112 (74.7) | 84 (80.0) |
Level 2 | 52 (26.4) | 36 (23.2) | 34 (26.6) | 55 (27.6) | 38 (25.3) | 21 (20.0) |
Level 3 | 0 | 0 | 0 | 2 (1.0) | 0 | 0 |
Pain/Discomfort | ||||||
Level 1 | 105 (53.3) | 96 (61.9) | 77 (60.2) | 114 (57.0) | 79 (52.3) | 63 (60.6) |
Level 2 | 85 (43.1) | 54 (34.8) | 51 (39.8) | 81 (40.5) | 69 (45.7) | 37 (35.6) |
Level 3 | 7 (3.6) | 5 (3.2) | 0 | 5 (2.5) | 3 (2.0) | 4 (3.8) |
Self-Care | ||||||
Level 1 | 184 (92.9) | 136 (87.7) | 115 (89.8) | 184 (92.5) | 131 (86.8) | 92 (87.6) |
Level 2 | 14 (7.1) | 19 (12.3) | 13 (10.2) | 13 (6.5) | 20 (13.2) | 12 (11.4) |
Level 3 | 0 | 0 | 0 | 2 (1.0) | 0 | 1 (1.0) |
Usual Activities | ||||||
Level 1 | 126 (63.6) | 93 (60.4) | 83 (64.8) | 122 (61.3) | 87 (57.6) | 71 (68.3) |
Level 2 | 65 (32.8) | 52 (33.8) | 45 (35.2) | 70 (35.2) | 61 (40.4) | 31 (29.8) |
Level 3 | 7 (3.5) | 9 (5.8) | 0 | 7 (3.5) | 3 (2.0) | 2 (1.9) |